<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Quinine: malaria; Malarone: malaria treatment; Riamet; Mefloquine: malaria: treatment; Doxycycline: malaria: treatment; Clindamycin: malaria treatment; Sulfadoxine, pyrimethamine with; Pyrimethamine: malaria: sulfadoxine with; Malarone: malaria treatment; Atovaquone: malaria; Proguanil: atovaquone with; Lumefantrine; Quinine: malaria; Artesunate; Clindamycin: malaria treatment; Clindamycin: malaria treatment; Artesunate" /><meta name="IX" content="Quinine: malaria; Malarone: malaria treatment; Riamet; Mefloquine: malaria: treatment; Doxycycline: malaria: treatment; Clindamycin: malaria treatment; Sulfadoxine, pyrimethamine with; Pyrimethamine: malaria: sulfadoxine with; Malarone: malaria treatment; Atovaquone: malaria; Proguanil: atovaquone with; Lumefantrine; Quinine: malaria; Artesunate; Clindamycin: malaria treatment; Clindamycin: malaria treatment; Artesunate" /><title>Falciparum malaria (treatment): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3913-falciparum-malaria-treatment.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3913-falciparum-malaria-treatment.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3913-falciparum-malaria-treatment.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3253-infections.htm">5 Infections</a> &gt; <a href="PHP3908-antiprotozoal-drugs.htm">5.4 Antiprotozoal drugs</a> &gt; <a href="PHP3911-antimalarials.htm">5.4.1 Antimalarials</a> &gt; <a href="PHP3912-treatment-of-malaria.htm">Treatment of malaria</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3912-treatment-of-malaria.htm" title="Previous: Treatment of malaria">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3915-benign-malarias-treatment.htm" title="Next: Benign malarias (treatment)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Falciparum malaria (treatment)</h1><?highlighter on?><div id="pC" class="jN"><p>Falciparum malaria (malignant malaria) is caused by <em>Plasmodium falciparum</em>. In most parts of the world <em>P. falciparum</em> is now resistant to chloroquine which should not therefore be given for treatment.</p> <p><strong>Quinine</strong>, <strong><em>Malarone</em></strong>® (proguanil with atovaquone), or <strong><em>Riamet</em></strong>® (artemether with lumefantrine) can be given <em>by mouth</em> if the patient can swallow and retain tablets and there are no serious manifestations (e.g. impaired consciousness); quinine should be given <em>by intravenous infusion</em> (see below) if the patient is seriously ill or unable to take tablets. Mefloquine is now rarely used for treatment because of concerns about resistance.</p> <ul class="cW"><li><p><em>Oral</em>. The adult dosage regimen for <strong>quinine</strong> <em>by mouth</em> is:<br />600 mg (of quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#PHP10670" class="tooltip PHP10670">(1)</a></cite>) every 8 hours for 5–7 days <em>together with or followed by</em><br /><em>either</em> <strong>doxycycline</strong> 200 mg once daily for 7 days<br /><em>or</em> <strong>clindamycin</strong> 450 mg every 8 hours for 7 days [unlicensed indication].<br />If the parasite is likely to be sensitive, <strong>pyrimethamine</strong> 75 mg with <strong>sulfadoxine</strong> 1.5 g as a single dose [unlicensed] may be given (instead of either clindamycin or doxycycline) together with, or after, a course of quinine.</p> </li></ul> <p>Alternatively, <strong><em>Malarone</em></strong>® or <strong><em>Riamet</em></strong>® may be given instead of quinine. It is not necessary to give doxycycline, clindamycin or pyrimethamine with sulfadoxine after <em>Malarone</em>® or <em>Riamet</em>® treatment.</p> <ul class="cW"><li><p>The adult dose of <strong><em>Malarone</em></strong>® <em>by mouth</em> is:<br />4 (‘standard’) tablets once daily for 3 days.</p> </li></ul> <ul class="cW"><li><p>The dose of <strong><em>Riamet</em></strong>® <em>by mouth</em> for adult with body-weight over 35 kg is:<br />4 tablets initially, followed by 5 further doses of 4 tablets each given at 8, 24, 36, 48, and 60 hours (total 24 tablets over 60 hours).</p> </li></ul> <ul class="cW"><li><p><em>Parenteral</em>. If the patient is seriously ill or unable to take tablets, or if more than 2 % of red blood cell are parasitized, <strong>quinine</strong> should be given <em>by intravenous infusion</em> [unlicensed]. The adult dosage regimen for quinine <em>by infusion</em> is:<br />loading dose<cite><a href="PHP3913-falciparum-malaria-treatment.htm#ID0ENDAFAA" class="tooltip ID0ENDAFAA">(2)</a></cite> of 20 mg/kg<cite><a href="PHP3913-falciparum-malaria-treatment.htm#ID0ELDAFAA" class="tooltip ID0ELDAFAA">(4)</a></cite> (up to maximum 1.4 g) of quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#PHP10670" class="tooltip PHP10670">(1)</a></cite> infused over 4 hours <em>then 8 hours after the start of the loading dose,</em> maintenance dose of 10 mg/kg<cite><a href="PHP3913-falciparum-malaria-treatment.htm#ID0EFDAFAA" class="tooltip ID0EFDAFAA">(5)</a></cite> (up to maximum 700 mg) of quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#PHP10670" class="tooltip PHP10670">(1)</a></cite> infused over 4 hours every 8 hours (until patient can swallow tablets to complete the 7-day course <em>together with or followed by either</em> doxycycline or clindamycin as above).</p> <p>Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous <strong>artesunate</strong> may be available for ‘named-patient’ use.</p> </li></ul> <div><h2>Children</h2><ul class="cW"><li><p><em>Oral.</em> <strong>Quinine</strong> is well tolerated by children although the salts are bitter. The dosage regimen for quinine <em>by mouth</em> for children is:</p> <p>10 mg/kg (of quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#PHP10670" class="tooltip PHP10670">(1)</a></cite>; max. 600 mg) every 8 hours for 7 days <em>together with or followed by</em><br /><strong>Clindamycin</strong> 7–13 mg/kg (max. 450 mg) every 8 hours for 7 days [unlicensed indication]<br /><em>or</em> in children over 12 years, <strong>doxycycline</strong> 200 mg once daily for 7 days</p> <p><em>or</em> if the parasite is likely to be sensitive, <strong>pyrimethamine</strong> with <strong>sulfadoxine</strong> as a single dose [unlicensed]: up to 4 years and body-weight over 5 kg, pyrimethamine 12.5 mg with sulfadoxine 250 mg; 5–6 years, pyrimethamine 25 mg with sulfadoxine 500 mg; 7–9 years, pyrimethamine 37.5 mg with sulfadoxine 750 mg; 10–14 years, pyrimethamine 50 mg with sulfadoxine 1 g; 14–18 years, pyrimethamine 75 mg with sulfadoxine 1.5 g</p> </li></ul><p>Alternatively, <strong><em>Malarone</em></strong>® or <strong><em>Riamet</em></strong>® may be given instead of quinine; it is not necessary to give clindamycin, doxycycline, or pyrimethamine with sulfadoxine after <em>Malarone</em>® or <em>Riamet</em>® treatment. The dose regimen for <em>Malarone</em>® <em>by mouth</em> for children over 40 kg is the same as for adults (see above); the dose regimen for <em>Malarone</em>® for smaller children is reduced as follows:</p><ul class="cW"><li><p>body-weight 5–9 kg, 2 ‘paediatric’ tablets once daily for 3 days; body-weight 9–11 kg, 3 ‘paediatric’ tablets once daily for 3 days; body-weight 11–21 kg, 1 ‘standard’ tablet once daily for 3 days; body-weight 21–31 kg, 2 ‘standard’ tablets once daily for 3 days; body-weight 31–40 kg, 3 ‘standard’ tablets once daily for 3 days.</p> </li></ul><p>The dose regimen of <em>Riamet</em>® <em>by mouth</em> for children over 12 years and body-weight over 35 kg is the same as for adults (see above). The dose regimen for <em>Riamet</em>® for children under 12 years is as follows:</p><ul class="cW"><li><p>body-weight 5–15 kg 1 tablet initially, followed by 5 further doses of 1 tablet each given at 8, 24, 36, 48, and 60 hours (total 6 tablets over 60 hours); body-weight 15–25 kg 2 tablets initially, followed by 5 further doses of 2 tablets each given at 8, 24, 36, 48, and 60 hours (total 12 tablets over 60 hours); body-weight 25–35 kg 3 tablets initially, followed by 5 further doses of 3 tablets each given at 8, 24, 36, 48, and 60 hours (total 18 tablets over 60 hours)</p> </li></ul><p><em>Parenteral</em>. The dose regimen for quinine <em>by intravenous infusion</em> for children is calculated on a mg/kg basis as for adults (see above). </p></div> <div id="PHP3914"><h2>Pregnancy</h2><p>Falciparum malaria is particularly dangerous in pregnancy, especially in the last trimester. The adult treatment doses of oral and intravenous quinine given above (including the loading dose) can safely be given to pregnant women. Clindamycin 450 mg every 8 hours for 7 days [unlicensed indication] should be given with or after quinine. Doxycycline should be avoided in pregnancy (affects teeth and skeletal development); pyrimethamine with sulfadoxine, <em>Malarone</em>®, and <em>Riamet</em>® are also best avoided until more information is available. Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ‘named patient’ use.</p></div> </div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3912-treatment-of-malaria.htm">Previous: Treatment of malaria</a> | <a class="top" href="PHP3913-falciparum-malaria-treatment.htm#">Top</a> | <a accesskey="]" href="PHP3915-benign-malarias-treatment.htm">Next: Benign malarias (treatment)</a> ►</div><ol class="cC"><li class="footnote" id="PHP10670"><p>Valid for quinine hydrochloride, dihydrochloride, and sulfate; not valid for quinine bisulfate which contains a correspondingly smaller amount of quinine.</p></li><li class="footnote" id="ID0ENDAFAA"><p>In intensive care units the loading dose can alternatively be given as quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#ID0EBANDAFAA" class="tooltip ID0EBANDAFAA">(3)</a></cite> 7 mg/kg infused over 30 minutes followed immediately by 10 mg/kg over 4 hours then (after 8 hours) maintenance dose as described.</p></li><li class="footnote" id="ID0EBANDAFAA"><p>Valid for quinine hydrochloride, dihydrochloride, and sulfate; not valid for quinine bisulfate which contains a correspondingly smaller amount of quinine.</p></li><li class="footnote" id="ID0ELDAFAA"><p><strong>Important:</strong> the loading dose of 20 mg/kg should <strong>not</strong> be used if the patient has received quinine or mefloquine during the previous 12 hours.</p></li><li class="footnote" id="ID0EFDAFAA"><p>Maintenance dose should be reduced to 5–7 mg/kg of quinine salt<cite><a href="PHP3913-falciparum-malaria-treatment.htm#ID0EBAFDAFAA" class="tooltip ID0EBAFDAFAA">(6)</a></cite> in patients with severe renal impairment, severe hepatic impairment, or if parenteral treatment is required for more than 48 hours.</p></li><li class="footnote" id="ID0EBAFDAFAA"><p>Valid for quinine hydrochloride, dihydrochloride, and sulfate; not valid for quinine bisulfate which contains a correspondingly smaller amount of quinine.</p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>